Correct Answer: A. 6-mercaptopurine
6-mercaptopurine (6-MP) is a purine analogue that acts as a true inhibitor of DNA synthesis. It is converted intracellularly to 6-MP ribonucleotide, which inhibits both de novo and salvage pathway purine synthesis by allosteric inhibition of HGPRT and PRPP amidotransferase. This blocks the formation of GTP and ATP precursors, preventing DNA polymerization. 6-MP is classified as an antimetabolite (specifically a purine antagonist) and is a cell-cycle phase-specific drug (S-phase). In Indian clinical practice, 6-MP is used as a maintenance therapy in acute lymphoblastic leukemia (ALL), particularly in pediatric patients, and as an immunosuppressant in autoimmune conditions like inflammatory bowel disease. Unlike the other options, which act through different mechanisms (intercalation, alkylation, or protein synthesis inhibition), 6-MP directly prevents the synthesis of DNA building blocks, making it the only true DNA synthesis inhibitor among the choices. The drug requires metabolic activation and is metabolized by xanthine oxidase, necessitating dose reduction when co-administered with allopurinol—a critical point in Indian pediatric oncology protocols.
Why the other options are wrong
B. Actinomycin — Actinomycin D is a DNA intercalating agent that binds to the DNA double helix and inhibits RNA synthesis (transcription), not DNA synthesis. It prevents RNA polymerase movement along the DNA template. While it does damage DNA, its primary mechanism is transcription inhibition, not blocking DNA replication. This is a common NBE trap—students confuse 'DNA damage' with 'DNA synthesis inhibition.' C. Mitomycin — Mitomycin is an alkylating agent that cross-links DNA strands after metabolic activation, causing strand breaks and preventing DNA replication indirectly. However, its mechanism is DNA damage/alkylation, not inhibition of DNA synthesis precursor formation. It acts as a prodrug requiring reduction and is phase-nonspecific. The trap here is that mitomycin does prevent DNA replication, but through a different pathway than true synthesis inhibitors. D. Asparaginase — Asparaginase is an enzyme that depletes asparagine, an amino acid essential for protein synthesis. It inhibits protein synthesis, not DNA synthesis. While protein depletion indirectly affects cell division, asparaginase has no direct effect on DNA synthesis machinery or nucleotide pools. This is a straightforward distractor—it targets a different macromolecule entirely.
High-Yield Facts
- 6-MP is a purine analogue antimetabolite that inhibits de novo and salvage pathway purine synthesis, directly blocking DNA precursor formation.
- Actinomycin D intercalates DNA and inhibits transcription (RNA synthesis), not DNA synthesis.
- Mitomycin is an alkylating agent that cross-links DNA strands, causing damage rather than inhibiting synthesis precursors.
- 6-MP requires xanthine oxidase metabolism—dose must be reduced to 25% when allopurinol is co-administered (critical in Indian pediatric ALL protocols).
- 6-MP is S-phase specific and used as maintenance therapy in ALL and as an immunosuppressant in IBD in Indian clinical practice.
- Asparaginase depletes asparagine and inhibits protein synthesis, not DNA synthesis.
Mnemonics
DNA Synthesis Inhibitors vs. Others AMPS = Antimetabolites (6-MP, 5-FU, MTX) inhibit synthesis; Alkylators (Mitomycin, Cyclophosphamide) damage DNA; Intercalators (Actinomycin, Doxorubicin) block transcription; Protein inhibitors (Asparaginase, Vinca) block protein synthesis. Use this to distinguish mechanism from outcome. 6-MP Memory Hook '6-MP = Purine Pretender' — it looks like a purine but blocks purine synthesis, starving the cell of DNA building blocks. Think 'fake purine, real block.'
NBE Trap
NBE pairs 'DNA synthesis inhibitor' with drugs that cause DNA damage (mitomycin, actinomycin) to trap students who confuse 'preventing DNA replication' with 'preventing DNA synthesis.' The key discriminator is that antimetabolites like 6-MP block the formation of precursors, while alkylators and intercalators damage existing DNA.
Clinical Pearl
In Indian pediatric oncology, 6-MP is the backbone of ALL maintenance therapy (typically 50 mg/m²/day). Always check for allopurinol co-administration and reduce 6-MP dose to 25%—this interaction is tested frequently in NEET PG and reflects real clinical practice in Indian cancer centers.
_Reference: KD Tripathi Ch. 62 (Anticancer Drugs); Robbins Ch. 7 (Cell Injury); Harrison Ch. 89 (Principles of Cancer Therapy)_